Earnings Summary

Madrigal Pharmaceuticals, Inc.’s revenue jumped NaN% since last year same period to $0Mn in the Q4 2023. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. has generated NaN% jump in its revenue since last 3-months.

Madrigal Pharmaceuticals, Inc.’s net profit fell -28.09% since last year same period to $-112.19Mn in the Q4 2023. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. has generated -13.63% fall in its net profits since last 3-months.

Madrigal Pharmaceuticals, Inc.’s net profit margin jumped NaN% since last year same period to -Inf% in the Q4 2023. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. has generated NaN% jump in its net profit margins since last 3-months.

Madrigal Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at -6.3 - a -19.32% fall from last quarter’s estimates.

Madrigal Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at -6.3.

Madrigal Pharmaceuticals, Inc.’s earning per share (EPS) fell -14.06% since last year same period to -5.68 in the Q4 2023. This indicates that the Madrigal Pharmaceuticals, Inc. has generated -14.06% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Madrigal Pharmaceuticals, Inc.’s return on assets (ROA) stands at -0.47.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Madrigal Pharmaceuticals, Inc.’s return on equity (ROE) stands at -1.24.